Versameb AG is a Basel, Switzerland–based biopharmaceutical company focused on the discovery and development of next-generation RNA-based drugs. Its proprietary VERSagile technology platform enables efficient development of functional mRNA molecules for customized protein expression and modification across therapeutic indications. The company plans to expand VERSagile into multiple indications and advance its lead program toward clinical studies. Versameb closed a CHF6.4m Seed C financing round, bringing total capital raised to date to CHF11.8m. Leadership includes CEO Prof. Dr. Friedrich Metzger; at the 2019 Annual Shareholder Meeting Dr. Reinhard Ambros was elected to the board and appointed Chairman, succeeding Roger Meier. The company recently appointed Dr. Isabel Ferreira as Chief Business Officer to lead global partnering and corporate development; she previously served as Director Global Business Development at Roche Partnering and held senior business development roles at a Dutch biotech that IPO'd on NASDAQ in 2013 and was acquired by BioMarin in 2015.

Total raised

$6M

Funding rounds

1

Latest round

Seed

Latest activity

Oct 2019